Health care reform took a turn for the better when members of key committees in both the U.S. Senate and House of Representatives recently recommended an approval pathway for biosimilars—products that attempt to be similar to an innovator biologic drug—while also preserving the hope for future medical treatments. Specifically, the committees agreed that to preserve … Continue reading “Protecting America’s Leadership in Biotech Discovery”
Author: James N. Thomas
Jim Thomas, based at Amgen's Seattle facility, is vice president of research, process and product development. He joined Amgen with the acquisition of Immunex in 2002 and currently leads the company’s Product and Process Development efforts at Amgen. He is responsible for teams at Amgen’s Washington state facilities as well as Thousand Oaks, California. A pioneer in the biotechnology industry, Dr. Thomas has more than 20 years of experience in the field. Dr. Thomas joined Immunex Corporation in 1991 as a scientist in the Molecular Biology and Gene Expression department. While at Immunex, Dr. Thomas also served as the director of Cell Sciences and as vice president of Process Science. Prior to Immunex, Dr. Thomas spent seven years at Genentech in Cell Culture Research and Development. Dr. Thomas received his Ph.D. from Purdue University and completed a post-doctorate fellowship at MIT.